Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Nestlé and IdB Holding S.p.A. sign VOWST® licensing deal in Europe

patients new therapies for high unmet medical needs." VOWST is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered LBP used to prevent Clostridioides difficile (C.diff) infection in individuals people 18 years of...

Ori Biotech and ImmuXell Announce Strategic Partnership and First Patient Dosed

to GMP on a single system — increasing throughput, improving quality, and reducing cost. Launched in 2024 and holder of an FDA Advanced Manufacturing Technology designation, IRO® is rapidly becoming the new standard in CGT manufacturing. About...

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

treatment due to adverse reactions. VYEPTI® (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing...

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

— including an oral version of Rebecsinib that would broaden patient access. Clinical Progress Rebecsinib has received FDA Investigational New Drug (IND) approval (IND #153126), and recruitment for the Phase 1 trial in patients with high-risk...

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced that it received U.S. Food and Drug Administration 510(k) clearance...

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

is the first and only non-replicating intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with high-risk BCG-unresponsive NMIBC with CIS, with or without papillary tumors (±Ta/T1), and is...

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from...

MinuteClinic highlights improved access and outcomes through its clinically supervised weight-loss program

health conditions before recommending individualized treatment plans. When clinically appropriate, providers may prescribe FDA-approved weight-loss medications, including GLP-1 therapies, alongside ongoing nutrition counseling and lifestyle...

Kerri McCullough Wood Named Chief Commercial Officer at Avid Bioservices

organization (CDMO) specializing in mammalian cell-culture manufacturing. Headquartered in the U.S. with a flawless FDA record, Avid is trusted by biopharmaceutical innovators worldwide for its agility, quality, and ability to navigate complex...

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

Inc. (PTx), a private, fully integrated biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or metastatic...

Miach Orthopaedics Appoints Jamal Rushdy as President & CEO

his tenure, Miach secured more than $60 million in funding, expanded commercial adoption of the BEAR Implant, and achieved FDA approval of key label updates to enable use in children and adolescents of any age and for partial ACL tears, as well as...

Avenacy Announces U.S. Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection

Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards. U.S. sales of Tranexamic Acid Injection were approximately $30.2 million for the...

Amazon Pharmacy Expands Same-Day Delivery and Kiosk Access for New Ozempic® Pill

that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and pickup...

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabete. Indicated not only to improve blood sugar, along with diet...

Incyte announces FDA approval of Jakafi XR for treating myelofibrosis, polycythemia vera, and graft-versus-host disease

Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who...

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

health, pioneering innovative treatments that address long-overlooked needs. With the launch of Addyi, the first ever FDA-approved treatment for Hypoactive Sexual Desire Disorder (HSDD), Sprout helped shift the conversation around women's sexual...

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

that are now treated in hospitals," said Pieter Muntendam MD, founder, President and CEO of SQ Innovation. "Following FDA approval in the United States in 2025, these European regulatory milestones reflect our commitment to bringing this...

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) and will begin commercial deployment of its FDA-cleared wound treatment, Hemastyl®, starting May 1, 2026. Clinical training across VA and DoD facilities will begin May 1,...

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely...

Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards for fungal-free survival at Day 90, showing non-inferiority of rezafungin vs....